FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Duarte Ira						2. Issuer Name and Ticker or Trading Symbol HERON THERAPEUTICS, INC. /DE/ [ HRTX]									k all applic Directo	cable)	g Person(s) to Iss 10% O Other (s		wner specify	
(Last) (First) (Middle) 4242 CAMPUS POINT COURT, SUITE 200						3. Date of Earliest Transaction (Month/Day/Year) 07/19/2024									below)		nanci	below)		
(Street) SAN DIEGO CA 92121					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									dividual or Joint/Group Filing (Check Applicable ) Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)					Ru	Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Tab	le I - Nor	n-Deriv	ative	Sec	uriti	ies Ac	quired,	Dis	posed o	of, or Be	nefi	cially	Owned	ł				
1. Title of Security (Instr. 3)  2. Transa Date (Month/D						ar) if	2A. Deemed Execution Date, f any Month/Day/Year		3. Transaction Code (Instr. 8)						5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) o	r P	rice	Transact (Instr. 3	tion(s)			,moa. 4)	
Common Stock 07/19/						/2024		М		3,875			(1)	104,127			D			
		T	able II -						,	•		, or Ben ible sec		•	Owned					
	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,		ransaction code (Instr.		wative urities uired or oosed D) tr. 3, 4	6. Date Ex Expiration (Month/Da	Date		and 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		1 5	B. Price of Derivative Gecurity Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisab		xpiration ate	Title	Amo or Num of Sha	nber						
Restricted Stock Units	\$0.00	07/19/2024			M			3,875	(2)		(2)	Common Stock	3,8	375	\$0.00	54,240	)	D		

## **Explanation of Responses:**

- 1. Each restricted stock unit represents a contingent right to receive one share of common stock
- 2. The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

/s/ Kathryn Lester Attorney-in-Fact for Ira Duarte

07/22/2024

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.